Jianmin Pharmaceutical Group Co.,Ltd.

600976

CNE000001HB7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
60.19 ^CNY	-2.62%		+3.49%	-7.75%

Apr. 19	Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 16	Jianmin Pharma Gets Nod to Market Asthma Drug	MT

Jianmin Pharmaceutical Group Co.,Ltd. intends to acquire Zhejiang Huafang Medical Care Co., Ltd from Holley Group Company Limited, Zhejiang Holley Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) for CNY 15.2 million.

August 16, 2022

Jianmin Pharmaceutical Group Co.,Ltd. (SHSE:600976) intends to acquire Zhejiang Huafang Medical Care Co., Ltd from Holley Group Company Limited, Zhejiang Holley Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) for CNY 15.2 million on August 15, 2022.

Latest news about Jianmin Pharmaceutical Group Co.,Ltd.

Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 19	CI
Jianmin Pharma Gets Nod to Market Asthma Drug	Apr. 16	MT
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Jianmin Pharmaceutical’s Drugs Remain Covered by China’s National Medical Insurance	Dec. 15	MT
Jianmin Pharmaceutical Earmarks 132 Million Yuan to Expand China Factory; Shares Jump 8%	Nov. 17	MT
Jianmin Pharma Gets Nod to Market Drug For Children's Acute Bronchitis	23-10-23	MT
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-20	CI
Jianmin Pharma Receives Nod to Market Oral Solution For Epilepsy Patients	23-10-17	MT
Jianmin Pharmaceutical Group Co.,Ltd.(XSSC:600976) added to S&P Global BMI Index	23-09-18	CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-08	CI
Jianmin Pharmaceutical Group Co.,Ltd. completed the acquisition of 6.13% stake in HeraMED Limited from Hua Li Pharmaceutical Group Co.,Ltd.	23-07-24	CI
Jianmin Pharma Gets Nod to Market Atomoxetine Hydrochloride Oral Solution; Shares Drop 3%	23-05-25	MT
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-17	CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-14	CI
Jianmin Pharma's Liver, Stomach Disease Drug Included in China’s Medical Insurance Catalog	23-01-19	MT
Jianmin Pharma to Buy 4.5% of Australia’s Hera Med for 8.4 Million Yuan	22-12-28	MT
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-21	CI
Jianmin Pharmaceutical Group Co.,Ltd. intends to acquire Zhejiang Huafang Medical Care Co., Ltd from Holley Group Company Limited, Zhejiang Holley Investment Management Co., Ltd. and Suzhou Yuanyi Zhiyuan Equity Investment Partnership (Limited Partnership) for CNY 15.2 million.	22-08-16	CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022	22-07-19	CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-04-15	CI
Jianmin Pharmaceutical Group Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-17	CI
Chinese Shares End Lower; Pharmaceutical Stlocks Suffer Huge Losses After WuXi Biologics' US Sanction	22-02-11	MT
Jianmin Pharmaceutical Group Co.,Ltd. intends to acquire 6.13% stake in HeraMED Limited from Hua Li Pharmaceutical Group Co.,Ltd. for AUD 2.1 million.	21-11-12	CI
Jianmin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021	21-10-21	CI

Chart Jianmin Pharmaceutical Group Co.,Ltd.

Duration

Period

Chart Jianmin Pharmaceutical Group Co.,Ltd.

More charts

Company Profile

JIANMIN PHARMACEUTICAL GROUP CO., LTD., formerly Wuhan Jianmin Pharmaceutical Groups Co. Ltd, is a China-based company, principally engaged in the research and development, manufacture, wholesale and retailing of pharmaceuticals. The Company operates its businesses through two segments, including Pharmaceutical Industry and Pharmaceutical Business. The Pharmaceutical Industry segment is engaged in the research and development and manufacture of pharmaceuticals. Its products are mainly applied in children, women and the elderly, among others. The Pharmaceutical Business segment is engaged in the wholesale and retailing of pharmaceuticals. Its products include traditional Chinese medicine, Western medicine, health products, medical equipment and chemical agents. It distributes its products mainly in domestic market.

Sector

Pharmaceuticals

Calendar

2024-08-13 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Jianmin Pharmaceutical Group Co.,Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

60.19 CNY

Average target price

87.74 CNY

Spread / Average Target

+45.77%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
JIANMIN PHARMACEUTICAL GROUP CO.,LTD.	-7.75%	1.27B
ELI LILLY AND COMPANY	+32.09%	693B
NOVO NORDISK A/S	+29.39%	584B
JOHNSON & JOHNSON	-1.34%	372B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+7.39%	294B
ASTRAZENECA PLC	+14.25%	239B
ROCHE HOLDING AG	-3.03%	211B
NOVARTIS AG	+10.02%	210B
AMGEN INC.	+8.49%	168B

Other Pharmaceuticals